Loading...
One of the principal advantages of non–vitamin K antagonist oral anticoagulants (NOACs) over warfarin is the lower rate of intracerebral hemorrhages (ICHs) observed in pivotal randomized trials. But because the absolute number of ICHs in these studies was relatively low, and because specific reversal agents for NOAC-related ICHs have only recently become available, it was unclear whether this advantage would be outweighed by NOAC-related ICHs that were more severe or that produced worse outcomes.
In this retrospective, partially industry-funded study, investigators used data from the American Heart Association/American Stroke Association Get with the Guidelines–Stroke (GWTG-Stroke) registry to identify a cohort of 141,311 patients who were h…